跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ENGERIX-B - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ENGERIX-B
Authorized
STANDARD
ENGERIX-B
GlaxoSmithKline Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
7a115f31ca1d5d12
Company
GlaxoSmithKline Inc
Type
Standard
Approval Details
Approval Id
7a115f31ca1d5d12
Drug Approval Canada Name
ENGERIX-B
Product Name
ENGERIX-B
Status
Marketed
Status Date
2019-10-07
Original Market Date
2019-10-07
Din
02487020
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
80:12.00
Atc Original
J07BC01 HEPATITIS B, PURIFIED ANTIGEN
Atc Name
j 07 bc 01
Aig Number
0119570002
Company Name
GlaxoSmithKline Inc
Company Address
800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path
/organization/glaxosmithkline-inc
Company Information
Pharmaceutical Company Name
GlaxoSmithKline Inc
Country Name
Canada
Province Name
Ontario
City Name
mississauga,ontario,country_ca
Address
800-100 Milverton Dr
Active Ingredients
HEPATITIS B SURFACE ANTIGEN (RECOMBINANT)
10 MCG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
7a115f31ca1d5d12
Type
Standard
Back to Health Canada Approvals